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Abstract
Shiga toxin-producing Escherichia coli (STEC) infections could be one of the causes of fetal morbimortality in pregnant
women. The main virulence factors of STEC are Shiga toxin type 1 and/or 2 (Stx1, Stx2). We previously reported that
intraperitoneal (i.p.) injection of rats in the late stage of pregnancy with culture supernatant from recombinant E. coli
expressing Stx2 and containing lipopolysaccharide (LPS) induces premature delivery of dead fetuses. It has been reported
that LPS may combine with Stx2 to facilitate vascular injury, which may in turn lead to an overproduction of nitric oxide
(NO). The aim of this study was to evaluate whether NO is involved in the effects of Stx2 on pregnancy. Pregnant rats were
i.p. injected with culture supernatant from recombinant E. coli containing Stx2 and LPS (sStx2) on day 15 of gestation. In
addition, some rats were injected with aminoguanidine (AG), an inducible isoform inhibitor of NO synthase (iNOS), 24 h
before and 4 h after sStx2 injection. NO production was measured by NOS activity and iNOS expression by Western blot
analysis. A significant increase in NO production and a high iNOS expression was observed in placental tissues from rats
injected with sStx2 containing 0.7 ng and 2 ng Stx2/g body weight and killed 12 h after injection. AG caused a significant
reduction of sStx2 effects on the feto-maternal unit, but did not prevent premature delivery. Placental tissues from rats
treated with AG and sStx2 presented normal histology that was indistinguishable from the controls. Our results reveal that
Stx2-induced placental damage and fetus mortality is mediated by an increase in NO production and that AG is able to
completely reverse the Stx2 damages in placental tissues, but not to prevent premature delivery, thus suggesting other
mechanisms not yet determined could be involved.
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Introduction
Shiga toxin-producing Escherichia coli (STEC) cause a significant
public health risk due to contamination of food and water supplies.
Gastrointestinal infection with STEC causes diarrhea and
hemorrhagic colitis, and is the leading cause of hemolytic uremic
syndrome (HUS), a systemic complication that is attributed to
expression of Shiga toxins (Stx) [1,2]. HUS is characterized by
hemolytic anemia, thrombocytopenia and acute renal failure, and
is recognized as the most common cause of acute renal failure in
children and the second leading cause of chronic renal failure in
Argentina [3,4]. Argentina has the highest rate of HUS in the
world, with a mean of 13.9 cases per 100,000 children younger
than 5 years of age [5]. Microorganisms isolated from children
with HUS are STEC and produce Stx1 and/or Stx2, with a
greater prevalence of Stx2 [6]. Recently, we have demonstrated
that the treatment of pregnant rats with a combination of Stx2 and
lipopolysacharide (LPS) on day 14–16 of gestation causes maternal
lethality in a dose-dependent manner and premature delivery of
dead fetuses 1–2 days post-injection [7]. In addition, we observed
fetoplacental resorption, placental abruption, intrauterine hemor-
rhage and fetal death were described [7]. In vivo and in vitro studies
have demonstrated that LPS may combine with Stx to facilitate
vascular injury [8], leading to a pathological cascade that involves
the production of nitric oxide (NO) [9,10]. NO has an important
role in implantation, decidualization, vasodilation and myometrial
relaxation during pregnancy; however, a massive production of
NO catalyzed by the inducible form of nitric oxide synthase
(iNOS) could cause pregnancy loss [11,12]. Aminoguanidine (AG),
an inhibitor of iNOS activity [13], totally reverses LPS-induced
embryonic resorption [12]. These observations led us to
investigate whether an up-regulation of NO production in rats
could be involved in Stx2-induced preterm delivery of dead
fetuses. Our results show that Stx2-induced placental toxicity and
fetus mortality is mediated by an increase in NO production.
Materials and Methods
Animals
To obtain timed pregnant females, both male and virgin female
Sprague-Dawley rats (250–300 g of body weight) from the School
of Veterinary Medicine animal facility of the University of Buenos
Aires were used.
Mating was performed by placing females in the cages of males
for several days. Day 1 of gestation was determined when sperm
was observed in the vaginal smear. Animals received food and
water ad libitum and were housed under controlled conditions of
light (12-h light, 12-h dark) and temperature (23–25uC). This study
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the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved by the
Institutional Committee for the Care and Use of Laboratory
Animals of the University of Buenos Aires (CICUAL, Permit
Number 1209–10).
Preparation of sStx2 and dosage of the cytotoxic activity
on Vero cells
The stx2 gene was cloned into pGEM-T-Easy (Promega, USA)
and recombinant E. coli DH5a expressing Stx2 were incubated
overnight at 37uC with shaking at 200 rpm in Luria-Bertani broth
(Difco Laboratories) supplemented with 100 mg/ml ampicillin
(Sigma Aldrich Co. USA). Bacterial cells were then removed by
centrifugation, and the resultant supernatant (sStx2) was filtered
through 0.22 mm pore size filter units (Millipore Corp, USA) and
assayed for toxicity to Vero cells as previously described [14]. The
50% cytotoxic dose (CD50) corresponds to the dilution required to
kill 50% of Vero cells. Stx2 cytotoxicity in sStx2 was approximately
1610
4 CD50/ml corresponding to 400 ng/ml when compared with
the cytotoxicity of pure Stx2 on Vero cells. Supernatant from E. coli
DH5a containing only the plasmid was used as control (sControl).
Lipopolysaccharide (LPS) content in the culture supernatant was
determined using the HEK-Blue LPS Detection Kit (InvivoGen,
San Diego, USA). A sample of 1 ml of supernatant contained 30 ng
of LPS (75 ng LPS/mg of Stx2 protein).
Determination of preterm delivery
In order to examine the effects of sStx2 on the delivery time and
fetal status, pregnant rats were intraperitoneally (i.p.) injected with
0.05–1.5 ml of sStx2 containing approximately 0.07–2 ng Stx2/g
body weight (wt) on day 14–16 of pregnancy (late stage). Control
rats were injected with the same volume of sControl. The rats were
individually housed under controlled conditions of light, humidity,
and temperature, with food and water available ad libitum.
Animals were observed every 30 minutes for any signs of
morbidity (piloerection, decreased movement), vaginal bleeding,
and/or preterm delivery (pups present in the cage) after sStx2 or
sControl administration. The beginning of preterm delivery was
defined as the delivery of the first pup.
Experimental design
Pregnant rats on days 15 of gestation were randomly divided
into three groups of five rats each. One group was i.p. injected
with 0.5 ml of sStx2 containing 0.7 ng Stx2/g body wt, another
with 1.5 ml of sStx2 containing 2 ng Stx2/g body wt, and the last
one with 0.5 or 1.5 ml of sControl. All rats were anesthetized and
killed by cervical dislocation 12 h after treatment, and the kidneys
and placentas were removed.
Determination of NOS activity
The conversion of L-[
14C]arginine into L-[
14C]citrulline was
used to quantify NOS activity according to a method previously
described [15]. Briefly, slices of tissue were weighed, homogenized
in a buffer containing 20 mM Hepes (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), 25 mM L-valine, 0.45 mM CaCl2,
and 1 mM DTT (dithiothreitol), and incubated at 37uC with
10 mM L-[
14C] arginine (0.3 mCi, Amersham Corp, UK) and
0.5 mM NADPH (nicotinamide adenine dinucleotide phosphate).
After 15 min, samples were centrifuged for 10 min at 10,000 g and
applied to a Dowex AG50-X8 column (Na
+ form, Bio-Rad Lab,
USA), and L-[
14C] citrulline was eluted. L-[
14C]Citrulline
radioactivity was measured by liquid scintillation counting.
Enzyme activity is reported as fmoles of L-[
14C]citrulline per mg
of protein per 15 min.
Western blot analysis
The tissues were homogenized on ice in an Ultra-Turrax
homogenizer in a buffer containing 50 mM Tris-HCl, pH 7.4,
10 mM EDTA, 150 mM NaCl, 1% Triton X-100 with 1 mg/ml
pepstatin A, 1 mg/ml leupeptin, 5 mg/ml aprotinin, 1 mM
phenylmethanesulfonylfluoride, all purchased from Sigma Aldrich
Corp (USA). Homogenates were pre-centrifuged at 2,500 g for
10 min at 4uC and the collected supernatants were additionally
centrifuged at 7,800 g for 10 min at 8uC. The supernatants were
collected and stored at 270uC until western blotting was
performed. Protein concentration was determined with the BCA
Protein Assay Kit (Pierce Biotechnology Inc, USA). One hundred
micrograms of protein were loaded in each lane. Samples were
separated on 7.5% (w/v) sodium dodecyl sulphate-polyacrylamide
gel by electrophoresis and transferred to a PVDF membrane (Bio-
Figure 1. Effects of Stx2 on pregnant rat delivery. Pregnant rats were injected with 0.05–1.5 ml of sStx2 containing 0.07–2 ng Stx2/g body wt
on day 14–16 of gestation. Delivery percentages were evaluated up to 12 days post-injection (n=6–12 rats for each concentration).
doi:10.1371/journal.pone.0015127.g001
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primary antibodies diluted 1:200 in phosphate-buffered saline
(PBS). The primary antibody was anti-iNOS rabbit polyclonal (BD
Transduction Lab). The membranes were then incubated for
60 min at room temperature with horseradish peroxidase-
conjugated goat anti-rabbit IgG antibody (1:3000, Bio-Rad,
USA) as secondary antibody. Proteins were detected using the
Amersham ECL detection system (Amersham Corp, UK). To
determine the uniformity of loading, protein blots were probed
with the monoclonal anti-b-actin antibody (1:4000, Sigma-Aldrich
Corp, USA). Band intensities were measured using the Quantity
One densitometry software package (Bio-Rad Lab, USA). Protein
bands were normalized to their respective b-actin bands. The
Western blots analysis was carried out with pool materials of 1–2
Figure 2. Nitric oxide synthase (NOS) activity in placental and kidney tissues after Stx2 injection. Pregnant rats on day 15 of gestation
were injected with 0.5 or 1.5 ml of sStx2 (0.7 or 2 ng Stx2/g body wt, respectively) and killed 12 h post injection. Control rats were injected with the
same volume of sControl. NOS activity was quantified by measuring the conversion of L-[
14C]arginine into L-[
14C] citrulline. Values corresponding to




Figure 3. Western blot for iNOS protein expression in placental tissues. Pregnant rats were injected with 0.5 or 1.5 ml of sStx2 (0.7 or 2 ng
Stx2/g body wt, respectively) on day 15 of gestation and killed 12 h post injection. Control rats were injected with the same volume of sControl. iNOS
expression in placental tissues was detected using a specific polyclonal anti-iNOS antibody. To determine the uniformity of loading, western blots
were probed with a monoclonal anti-b-actin antibody. Each value represents a pool of five animals. (A) Representative gel for iNOS expression. (B)
Densitometric analysis of the bars. Values correspond to the mean of four different pools of five animals 6 SEM. *P,0.01 vs controls.
doi:10.1371/journal.pone.0015127.g003
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experimental condition. The experiments were repeated 4 times.
Light microscopy
Freshly removed placentas were fixed for 48 h in formol buffer
10% in0.1 M PBS pH 7.4. The tissue sections were dehydrated and
embedded in paraffin. Sections of 5 mm were made by a microtome
(Leica RM 2125, Wetzlar, Germany) and mounted on 2% silane-
coated slides.The sectionswerestainedwith hematoxylin–eosin,and
observed by light microscopy (Nikon Eclipse 200, NY, USA).
iNOS immunohistochemistry
The samples were blocked of endogenous peroxidase with
hydrogen peroxide 0.3% in methanol for 10 min and rinsed with
PBS. Then, the slides were pre-incubated with non-immune rabbit
serum diluted in PBS (1:100) in a humidity chamber at room
Figure 4. Immunolocalization of iNOS in placental tissues. Pregnant rats were injected with 0.5 ml of sControl or sStx2 (0.7 ng Stx2/g body
wt) on day 15 of gestation and killed 12 h post injection. iNOS was detected in trophoblastic giant cells (A, black arrowhead) and glycogen cells (B;
black arrowhead) of placentas from control rats. An increased label of iNOS in glycogen cells (C–D, black arrowhead) was observed in placentas from
Stx2-treated rats. Original magnification: A and C 6200, B and D 61000.
doi:10.1371/journal.pone.0015127.g004
Figure 5. In vivo effects of AG on NOS activity in placental tissues. Pregnant rats were injected with 0.5 ml of sStx2 (0.7 ng Stx2/g body wt)
on day 15 of gestation and killed 12 h post injection. One group was treated with AG (100 mg/g body wt) 24 h before and 4 h after sStx2
administration. Another was treated only with AG (control AG). Control rats were treated with PBS 24 h before and 4 h after administration of 0.5 ml
of sControl. Values are the mean 6 SEM (n=4).
*P,0.001 vs other experimental conditions.
doi:10.1371/journal.pone.0015127.g005
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polyclonal antibody (BD Transduction Lab, USA). The antibody
was diluted 1:50 in PBS and incubated in a humidity chamber at
4uC overnight. The immunoperoxidase technique was then
performed following the protocol for the RTU Vectastain kit
(Vector Corp, UK). The antigen was revealed by diaminobenzi-
dine (DAB, Vector Corp). Finally, the sections were dehydrated,
counterstained and mounted for observation.
Determination of AG effects on Stx2-treated pregnant
rats
To study the effects of AG on the Stx2-treated pregnant rats, the
following experimental protocol was used. Rats were i.p. injected
with 0.5 or 1.5 ml of sStx2 (0.7 ng or 2 ng Stx2/g body wt) on day
15 of gestation. Some of them were treated with 100 mg AG/g
body wt 24 h before and 4 h after injection. Some animals were
killed 12 h later to evaluate NOS activity and iNOS expression, as
well as microscopic alteration of placenta tissues. The other rats
were killed at 48 h to observe the fetal status. Gestational sacs were
opened and the fetuses and placentas were evaluated macroscop-
ically. The remaining rats were observed up to delivery time. The
data were compared with those obtained when the rats were
injected with 1.5 ml of sControl.
Statistical analysis
Statistical analysis was performed using the Graph Pad Prism
Software (San Diego, CA, USA). Comparisons between values of
different groups were performed using one-way ANOVA. Signifi-
cance was determined using Tukey’s multiple comparison tests for
unequal replicates or Student’s t-test. Statistical significance was set at
P,0.05.
Results
Preterm delivery induced by Stx2 is dependent on toxin
concentration
Figure 1 shows deliveries of pregnant rats after injection with
sStx2 containing different doses of Stx2. All the rats (100%)
injected with 1.3 and 2 ng Stx2/g body wt exhibited early
premature delivery of dead fetuses (day 16–17 of gestation). In
contrast, 100% of rats injected with 0.07 and 0.13 ng Stx2/g body
wt delivered live fetuses at term (day 22–23 of gestation). Rats
injected with sControl also delivered fetuses at term. It is
noteworthy that the injection of 0.7 ng Stx2/g body wt induced
preterm delivery of live fetuses on day 21 of gestation in 50% of
the Stx2-treated rats, although the neonates did not survive. These
results demonstrate that systemic administration of sStx2 causes
fetal death in a dose-dependent fashion, without causing maternal
lethal effects.
Effect of sStx2 on NOS activity and iNOS expression
To investigate the role of NO in sStx2-induced preterm
delivery we analyzed NOS activity by the conversion of L-
[
14C]arginine into L-[
14C]citrulline. We observed a significant
increase in NOS activity in placental tissues of rats injected with
sStx2 containing 0.7 ng and 2 ng Stx2/g body wt and killed 12 h
after injection (Figure 2). The increase in NOS activity was also
observed in kidney tissues of rats injected with 2 ng Stx2/g body
wt (Figure 2), although it was not enough to alter the renal
functional parameters and the microscopic appearance of kidneys
(data not shown).
Inducible NOS (iNOS) protein was detected as a 130 kDa
band by western blot in placental tissues from both control and
Figure 6. In vivo effect of AG on iNOS protein expression in placental tissues. Pregnant rats were injected with either 0.5 ml (0.7 ng Stx2/g
body wt) or 1.5 ml of sStx2 (2 ng Stx2/g body wt) on day 15 of gestation and killed 12 h post injection. Some animals of each Stx2 concentration
were treated with AG (100 mg/g body wt) 24 h before and 4 h after injection of sStx2, whereas others were treated with AG alone. Control rats were
treated with PBS 24 h before and 4 h after injection of sControl. (A) Representative gel for iNOS expression. (B) Densitometric analysis of the bars.
Values correspond to the mean of four different pools of five animals 6 SEM.
*P,0.001 vs 0.7 ng Stx2/g body wt,
**P,0.05 vs 2 ng Stx2/g body wt.
doi:10.1371/journal.pone.0015127.g006
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expression of iNOS significantly increased at 0.7 ng Stx2/g body
wt and even more at 2 ng (Figure 3B), thus indicating the
relationship between toxin doses and NOS activity. iNOS
protein was not detected in kidney tissues of rats injected with
either sControl or sStx2 (Figure 3B). Therefore, only placental
tissues of control and sStx2-treated rats were processed by
immunochemistry (Figure 4). In rats treated with sControl, iNOS
label was detected in trophoblastic giant cells (Figure 4A; black
arrowhead) and glycogen cells (Figure 4B; black arrowhead).
Rats treated with 0.7 ng Stx2/g body wt showed an increase in
iNOS labeling in glycogen cells (Figure 4C–D, black arrowhead).
Similar results were observed using 2 ng Stx2/g body wt (data
not shown).
Effect of AG on NOS activity and iNOS protein expression
The increase in NOS activity detected in placental tissues after
injection of sStx2 containing 0.7 ng Stx2/g body wt decreased
significantly when pregnant rats were treated with 100 mg AG/g
body wt 24 h before and 4 h after Stx2 injection (Figure 5).
The treatment with AG also decreased the iNOS protein
expression observed in placentas from rats injected with 0.7 ng or
2 ng Stx2/g body wt. Values returned to the same levels as those
observed inplacentasfromcontrol rats(Figure6). BothNOS activity
and iNOS expression values in placental tissues from AG-treated
animals were similar to those observed in controls rats (Figure 6).
Macroscopic evaluation of the feto-maternal unit after
AG treatment
Uteri and fetuses from pregnant rats injected with sStx2 (2 ng
Stx2/g body wt) showed intrauterine hemorrhage and fetal death
48 h post injection (Figure 5C and D). Treatment with 100 mg
AG/g body wt 24 h before and 4 h after sStx2 injection caused a
significant reduction of Stx2 effects on the feto-maternal unit
(Figure 7E and F). Uteri and fetuses from control rats showed
normal fetal growth (Figure 7A and B).
Figure 7. Macroscopic evaluation of pregnant rats treated with AG and sStx2. Uteri and fetuses from pregnant rats injected with 1.5 ml
sStx2 containing 2 ng Stx2/g body wt showed intrauterine hemorrhage and fetal death 48 h after sStx2 injection (C, D). The treatment with 100 mg
AG/g body wt 24 h before and 4 h after sStx2 injection caused significant reduction of the toxin effects on the feto-maternal unit (E, F). Uteri and
fetuses from control rats showed normal fetal growth (A, B).
doi:10.1371/journal.pone.0015127.g007
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Placentas from rats injected with 0.7 or 2 ng Stx2/g body wt
and killed 12 h post injection presented necrotic areas (Figure 8A
and B, respectively) as compared with those from control animals
(Figure 8C). In contrast, the placentas from rats treated with
100 mg AG/g body wt 24 h before and 4 h after injection with
either 0.7 or 2 ng Stx2/g body wt (Figure 8D and E, respectively)
presented normal morphology indistinguishable from the controls
(Figure 8C).
Effect of AG treatment on the preterm delivery induced
by sStx2
Treatment with 100 mg AG/g body wt 24 h before and 4 h
after sStx2 injection containing 2 ng Stx2/g body wt did not
prevent the premature delivery of dead fetuses. In contrast, all the
pregnant rats treated only with AG or sControl delivered normal
live pups on days 22 or 23 of gestation. After Stx2-treatment, all
rats were able to become pregnant and deliver normal pups at
term.
Discussion
Our data show that sStx2 (a combination of Stx2 and LPS)
induces a significant increase in NO production and levels of
iNOS protein in placental tissues from pregnant rats, suggesting
overproduction of NO plays an important role in sStx2-induced
placental toxicity and fetal mortality [7]. Some authors have
described high concentrations of NO resulting from the output of
iNOS have been described in the pathophysiology of LPS-
mediated fetal resorption [12,16]. These authors demonstrated
that LPS causes 100% embryonic resorption in mice, and that this
was totally blocked by AG administration 24 h before and 4 h
after LPS injection. In our experiments, AG prevented both the
overproduction of NO by inhibiting iNOS and the histological
damages in placenta observed after sStx2 treatment.
NO is produced from L-arginine under the catalytic control of
nitric oxide synthase (NOS). Three NOS isoforms have been
identified: the endothelial (eNOS) and neuronal (nNOS) isoforms,
which are responsible for basal, i.e. constitutive, NO production,
and iNOS, which is activated by a variety of agonists including
LPS and tumor necrosis factor (TNF). In contrast to the
constitutive NOS isoforms, iNOS is thought to account for the
increased NO production seen in pathological states [17].
Although there are several clinical studies on the enhanced NO
productioninpatientswithHUS[18,19],itsrole inthepathogenesis
ofthe syndromehasnotyetbeen assessed.Ithasbeen described that
Stx down-regulates eNOS but up-regulates iNOS in cultured
human aortic endothelial cells [20]. In contrast, Stx reduces both
eNOS and iNOS in human glomerular endothelial and mesangial
cells [21]. In a baboon model of Stx-mediated HUS [22], NO
production (measured as urinary NO) increased during the initial
12 hours after Stx1 injection and then decreased below baseline
values. In an HUS mouse model obtained by Stx2-injection, NO
overproduction was attributed to endothelial injury and/or the
inflammatory response associated with iNOS activity. However
NOS inhibition caused an increase in Stx2-mediated renal damages
and lethality [23]. In our experiments, the lack of iNOS expression
in renal tissues of sStx2-treated pregnant rats in combination with a
normal renal physiology and histology indicates the inability of Stx2
to affect the mother’s kidneys. The complete (100%) maternal
survival at the sStx2 doses used also show that the brain was not
affected. The fact that Stx2 susceptibility in the kidney and brain is
lower than in the placenta could be the consequence of a high blood
flow distribution to the feto-placental unit. Since Stx2 may be
captured in the placental and embryonic tissues, its availability
(concentration) in blood necessary to cause the effects on other
target organs described in non-pregnant rats treated with similar
sStx2 doses is decreased [24].
Here we found that AG did not prevent premature delivery,
thus indicating that other mechanisms not yet determined could be
Figure 8. Histology of the placentas from pregnant rats treated with AG and sStx2. Placentas from pregnant rats treated with 0.7 or 2 ng
Stx2/g body wt presented necrotic areas (A and B, black arrows) as compared with controls (C). Placentas from rats treated with 100 mg AG/g body wt
plus 0.7 (D) or 2 ng (E) Stx2/g body wt did not show histological changes compared with controls (C). H&E. Original magnification: 6200.
doi:10.1371/journal.pone.0015127.g008
Nitric Oxide in Stx2 Effects on Rat Pregnancy
PLoS ONE | www.plosone.org 7 December 2010 | Volume 5 | Issue 12 | e15127involved. It is well known that Stx may act in concert with LPS to
elicit cellular dysfunction [25]. Stx can induce the production of
tumor necrosis factor (TNF) and interleukins-1 (IL-1) and –6 (IL-
6), by macrophages rendering the endothelial cells more sensitive
to the toxin [26,27]. It is possible that cytokine stimulation caused
by sStx2 may be responsible for premature delivery. Many studies
conducted in human and experimental animals have established
that a correct balance of cytokines at the maternal-fetal interface is
an essential requirement for proper placental development and,
therefore, reproductive success [28,29]. Additionally, there is
evidence supporting key roles of prostaglandins (PGs) [30,31].
Changes in uterine PG production appear to be involved in the
regulation of myometrial activity during pregnancy and labor.
Thus, further studies about cytokines and PG induction in the
placenta, uterus and fetus will be necessary to address whether
these pro-inflammatory mediators are involved in the premature
delivery observed in response to Stx2. Finally, we cannot discard
that NO could react with the superoxide radical and generate
peroxynitrite, a key oxidant and nitrating molecule, which could
initiate toxic reactions by introducing tyrosine nitration [32].
In summary, the present results allow us to conclude that the
Stx2-induced premature delivery in rats in the late gestational
stage is, at least in part, mediated by an increase in NO production
resulting from the output of iNOS.
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